Preliminary evidence indicates that tau measurements in the CSF and via PET correlate in the dementia stage of AD, but less clearly in the preclinical and mild cognitive impairment stages of the disease (Mattsson et al., 2017). The gene discussed is MAPT; the disease is Alzheimer disease.